Evidence map›Paper›PMID 27437997›Full record

ArticlePloS one2016

Hba1c, Blood Pressure, and Lipid Control in People with Diabetes: Japan Epidemiology Collaboration on Occupational Health Study.

Huanhuan Hu, Ai Hori, Chihiro Nishiura, Naoko Sasaki, Hiroko Okazaki, Tohru Nakagawa, Toru Honda, Shuichiro Yamamoto, Kentaro Tomita, Toshiaki Miyamoto and 20 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Glucose Regulation Beyond HbADiabetes care · 2021
    Article
  16. Article
  17. RETRACTED: Curative Effect of Catechin Isolated fromMolecules (Basel, Switzerland) · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 12 institutions in 1 country.

Huanhuan HuDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Ai HoriTokyo Gas Co., Ltd., Tokyo, Japan.
Chihiro NishiuraTokyo Gas Co., Ltd., Tokyo, Japan.
Naoko SasakiMitsubishi Fuso Truck and Bus Corporation, Kanagawa, Japan.
Hiroko OkazakiMitsui Chemicals, Inc., Tokyo, Japan.
Tohru NakagawaHitachi, Ltd., Ibaraki, Japan.
Toru HondaHitachi, Ltd., Ibaraki, Japan.
Shuichiro YamamotoHitachi, Ltd., Ibaraki, Japan.
Kentaro TomitaMitsubishi Plastics, Inc., Tokyo, Japan.
Toshiaki MiyamotoNippon Steel & Sumitomo Metal Corporation Kimitsu Works, Chiba, Japan.
Satsue NagahamaAll Japan Labour Welfare Foundation, Tokyo, Japan.
Akihiko UeharaYAMAHA CORPORATION, Shizuoka, Japan.
Makoto YamamotoYAMAHA CORPORATION, Shizuoka, Japan.
Taizo MurakamiMizue Medical Clinic, Keihin Occupational Health Center, Kanagawa, Japan.
Chii ShimizuMizue Medical Clinic, Keihin Occupational Health Center, Kanagawa, Japan.
Makiko ShimizuMizue Medical Clinic, Keihin Occupational Health Center, Kanagawa, Japan.
Masafumi EguchiFurukawa Electric Co., Ltd., Tokyo, Japan.
Takeshi KochiFurukawa Electric Co., Ltd., Tokyo, Japan.
Teppei ImaiAzbil Corporation, Tokyo, Japan.
Akiko OkinoAzbil Corporation, Tokyo, Japan.
Keisuke KuwaharaDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Ikuko KashinoDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Shamima AkterDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Kayo KurotaniDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Akiko NanriDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Isamu KabeFurukawa Electric Co., Ltd., Tokyo, Japan.
Tetsuya MizoueDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Naoki KunugitaNational Institute of Public Health, Saitama, Japan.
Seitaro DohiMitsui Chemicals, Inc., Tokyo, Japan.
Japan Epidemiology Collaboration on Occupational Health Study Group
National Center for Global Health and Medicine · JPFurukawa Electric (Japan) · JPHitachi (Japan) · JPKeihin (Japan) · JPAzbil (Japan) · JPMitsui Chemicals (Japan) · JPTokyo Gas (Japan) · JPYamaha (Japan) · JPMitsubishi Motors (Japan) · JPMitsubishi Plastics (Japan) · JPNational Institute of Public Health · JPNippon Steel (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe control of blood glucose levels, blood pressure (BP), and low-density lipoprotein cholesterol (LDL-C) levels reduces the risk of diabetes complications; however, data are scarce on control status of these factors among workers with diabetes. The present study aimed to estimate the prevalence of participants with diabetes who meet glycated hemoglobin (HbA1c), BP, and LDL-C recommendations, and to investigate correlates of poor glycemic control in a large working population in Japan.

methodsThe Japan Epidemiology Collaboration on Occupational Health (J-ECOH) Study is an ongoing cohort investigation, consisting mainly of employees in large manufacturing companies. We conducted a cross-sectional analysis of 3,070 employees with diabetes (2,854 men and 216 women) aged 20-69 years who attended periodic health examinations. BP was measured and recorded using different company protocols. Risk factor targets were defined using both American Diabetes Association (ADA) guidelines (HbA1c < 7.0%, BP < 140/90 mmHg, and LDL-C < 100 mg/dL) and Japan Diabetes Society (JDS) guidelines (HbA1c < 7.0%, BP < 130/80 mmHg, and LDL-C < 120 mg/dL). Logistic regression models were used to explore correlates of poor glycemic control (defined as HbA1c ≥ 8.0%).

resultsThe percentages of participants who met ADA (and JDS) targets were 44.9% (44.9%) for HbA1c, 76.6% (36.3%) for BP, 27.1% (56.2%) for LDL-C, and 11.2% (10.8%) for simultaneous control of all three risk factors. Younger age, obesity, smoking, and uncontrolled dyslipidemia were associated with poor glycemic control. The adjusted odds ratio of poor glycemic control was 0.58 (95% confidence interval, 0.46-0.73) for participants with treated but uncontrolled hypertension, and 0.47 (0.33-0.66) for participants with treated and controlled hypertension, as compared with participants without hypertension. There was no significant difference in HbA1c levels between participants with treated but uncontrolled hypertension and those with treated and controlled hypertension.

conclusionData from a large working population, predominantly composed of men, suggest that achievement of HbA1c, BP, and LDL-C targets was less than optimal, especially in younger participants. Uncontrolled dyslipidemia was associated with poor glycemic control. Participants not receiving antihypertensive treatment had higher HbA1c levels.

Indexed as

Blood PressureCooperative BehaviorOccupational HealthAdultAgedAntihypertensive AgentsDiabetes MellitusFemaleGlycated HemoglobinHumansHypolipidemic AgentsJapanLipidsMaleMiddle AgedPrevalenceAntihypertensive AgentsGlycated HemoglobinHypolipidemic AgentsLipids

Identifiers

PMID27437997
PMCPMC4954688
OpenAlexW2502693647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.